Skip to main content
D

Daiken Biomedical Co., Ltd. — Investor Relations & Filings

Ticker · 7780 TW Manufacturing
Open in API
Filings indexed 21 across all filing types
Latest filing 2026-04-10 Director's Dealing
Country TW Taiwan
Listing TW 7780

About Daiken Biomedical Co., Ltd.

https://www.daikenshop.com

Daiken Biomedical Co., Ltd. (Daiken Bio) is a specialized developer of high-quality health supplements and nutritional solutions. The company utilizes a multidisciplinary research and development team comprising medical doctors, PhD experts, and nutritionists. Its product formulations are grounded in scientific evidence, drawing from thousands of international peer-reviewed journals to ensure efficacy and safety. Daiken Bio offers a diverse portfolio, including high-concentration rTG fish oil, Maca extracts, probiotics, lutein, and specialized vitamin complexes. These solutions address various health concerns such as cardiovascular support, metabolic regulation, vision health, and digestive wellness. The company emphasizes the use of internationally patented raw materials and rigorous SGS quality testing. By integrating advanced delivery technologies like slow-release systems, Daiken Bio provides targeted nutritional support for children, adults, and the elderly.

Recent filings

Filing Released Lang Actions
115年03月內部人持股異動(事後)
Director's Dealing Classification · 1% confidence The document is a public insider shareholding disclosure listing company insiders (chairman, directors, managers, independent directors, etc.) along with their shareholdings at appointment, last month, and changes during the month. This aligns with a Director’s Dealing (insider transactions) filing rather than a company report or financial statement. It is not a share buyback, but an insider trading disclosure, so it falls under the Director’s Dealing category.
2026-04-10 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 1% confidence The document is a Taiwanese “公開資訊觀測站” disclosure of internal persons’ shareholdings and pledge status (directors, supervisors, major shareholders, management). It lists “選任時持股” vs “目前持股”, “設質股數” and related insider holdings details. This is an insider shareholding / dealings report, matching the Director’s Dealing category.
2026-04-10 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure filed to Taiwan’s Market Observation Post System (公開資訊觀測站) showing the company’s and subsidiaries’ loans and endorsement/guarantee balances (all zero). It is neither an earnings/annual report nor a capital change or dividend notice but a routine regulatory announcement of guarantee exposures. It does not fit any more specific category, so it falls under the fallback “Regulatory Filings” (RNS).
2026-04-10 Chinese
115年3月營業收入
Regulatory Filings Classification · 0% confidence The provided text is an error/security access message with no corporate disclosures, financial data, or regulatory content. It does not match any specific filing type. Per fallback guidelines, this should be classified as a general regulatory filing (RNS).
2026-04-10 Chinese
114年第4季海外子公司投資
Interim / Quarterly Report Classification · 1% confidence The document is a financial disclosure from the Taiwan Stock Exchange's 'Market Observation Post System' (公開資訊觀測站). It provides specific financial data regarding the company's investments in overseas subsidiaries for the 4th quarter of the 114th year (Republic of China calendar). It contains detailed tables of investment balances, shareholding percentages, and recognized investment gains/losses. Since it provides substantive financial data for a specific period (Q4) rather than just an announcement of a report, it is classified as an Interim/Quarterly Report (IR). Q4 2025
2026-03-31 Chinese
更正115年1月關係人交易申報明細
Regulatory Filings Classification · 1% confidence The document is a corporate disclosure filed via the Taiwan ‘公開資訊觀測站’ system. It corrects previously reported related-party transaction amounts (“更正115年1月關係人交易申報明細”) and provides updated figures. There is no indication that this is a full financial report, earnings release, board change, or any other specialized filing; rather, it is a miscellaneous regulatory update/correction. This falls under the fallback category “Regulatory Filings” (RNS).
2026-03-31 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.